Code intelligence

J2507 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance matched to code J2507.

Critical code riskView HCPCS detail

Signal breakdown

1 shown · 1 total in platform

Risk: Critical

Critical

100%

High

Routine

Low

New this month

alerts added in last 30 days

Effective soon

—

no upcoming deadlines

FDA Approval: KRYSTEXXA (PEGLOTICASE) — Type 1 - New Molecular Entity

Policy FDA-BLA125293 · Rheumatology

Critical

New FDA drug approval. Coverage and billing pathway depend on the FDA label and applicable Medicare LCDs/NCDs — for very recent approvals the label may not be posted yet. Verify against the FDA label and current coverage policy before billing.

View alert

Audit documentation

Building an audit file that includes J2507?

The Tripwire Audit Pack exports 12 months of Rheumatology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

Get the Rheumatology audit pack — $349One-time purchase · not a subscription